ORLANDO — Regeneron is facing another twist in its roller-coaster ride to win US approval of its lymphoma treatment, odronextamab, after a series of regulatory and manufacturing hurdles.
Earlier in 2025, the Tarrytown, NY, drugmaker said ...
↧